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Introduction
Since the successful transplantation of umbilical cord
blood from a newborn girl to her 5-year-old brother with
Fanconi’s anemia at the St. Louis Hospital in Paris in
1988, fetal cord blood stem cell research and transplan-
tation have taken an increasing share of the limelight [1].
Compared with adults’ hematopoietic stem cells, those
in fetal cord blood have distinct advantages, including
the capacity of forming more colonies in culture, a high
cell-cycle rate, autocrine production of growth factors,
and long telomeres. Cord blood CD34+38– cell telomere
length is around 12 kb, whereas bone marrow stem cell
telomere length is around 8 kb [2]. However, the draw-
back of stem cells from fetal cord blood is their limited
availability and quantity (average, 70–100 mL). Bone
marrow and umbilical cord blood contain 1–3% stem
cells, while only 0.1% of adult peripheral blood contains
stem cells.
Pathogens detected in fetal cord blood represent
fetal intrauterine infection. The infections might have
originated from ascending maternal infection or indirect
infection from the maternal sexual partner with sub-
sequent fetal swallowing or absorption from infected
amniotic fluid. Although the placenta serves as a filter
for the fetus to prevent pathogens of large particulate
matter, pathogens with a molecular weight less than
1,000 Da can pass to the fetus.
During pregnancy, cell-mediated immunity under-
goes selective inhibition. On the one hand, this ensures
fetal survival within the maternal body; on the other
hand, this decreases maternal immunity from patho-
genic infections [3].
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SUMMARY
Objective: To evaluate the rates of infection of asymptomatic fetuses and mothers through fetal cord blood and
maternal blood examination results.
Materials and Methods: Quantitative PCR (Q-PCR) was used to detect pathogens in maternal peripheral
blood and fetal cord blood after delivery of term pregnancy at Buddhist Tzu Chi Medical Center, Hualien,
between July 2002 and June 2003.
Results: We used Q-PCR to detect pathogens in 29 samples of maternal blood. The maternal hepatitis B virus
(HBV) DNA detection rate was 51.72% (15/29); for human cytomegalovirus DNA, the detection rate was 10.34%
(3/29) and for Chlamydia trachomatis DNA the detection rate was 3.45% (1/29). No Neisseria gonorrhoeae DNA was
detected. Whereas, in 29 samples of paired fetal cord blood, the detection rates were 27.59% (8/29), 10.34%
(3/29), and 3.45% (1/29) for HBV DNA, C. trachomatis DNA, and N. gonorrhoeae DNA, respectively. No human
cytomegalovirus DNA was detected in fetal cord blood.
Conclusion: Our results revealed an unexpectedly high incidence of pathogens in fetal cord blood. Screening 
for the above pathogens in donor cord blood in cord blood banks using Q-PCR is strongly urged to decrease
morbidity and mortality rates in fetal cord blood stem cell transplant recipients. [Taiwanese J Obstet Gynecol
2006;45(2):114–119]
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Recipients of hematopoietic stem cell transplants
might contract infections, fevers, and other nonimmune
rejection-related symptoms. These infections are impor-
tant factors affecting transplant success. Further, the
recipients are usually immunocompromised, which incre-
ases susceptibility to infections [4].
In our study, we used quantitative PCR (Q-PCR) to
detect pathogens in pregnant women and fetal cord
blood. The pathogens studied were hepatitis B virus
(HBV), human cytomegalovirus, Chlamydia trachomatis,
and Neisseria gonorrhoeae. The goals of this study were to
understand the rates of infection of sexually transmitted
pathogens in pregnant women and the umbilical cord
blood, to prevent fetal cord blood transplants from
infecting their recipients, and to decrease morbidity and
mortality rates in fetal cord blood transplant recipients.
Materials and Methods
Sample studied
With informed consent, 2 mL of peripheral blood sam-
ples from 29 healthy mothers after delivery of their term
singleton infants and paired 5 mL umbilical cord blood
were collected during delivery at Hualien Buddhist Tzu-
Chi General Hospital between January 2002 and June
2003. All were stored in 1.5-mL sodium heparin-
containing vacutainers (BD, Franklin Lakes, NJ, USA),
and kept in a refrigerator maintained at 4 C. All samples
were sent to the laboratory within 24 hours of collection,
where 2 mL of blood was placed in 2 mL tubes and cen-
trifuged at 3,000 rpm for 15 minutes. The serum on top
was then separated into clean test tubes kept at –20 C
for reserve purposes. The study protocol was approved
by the Hospital Research Ethics Committee.
Purification of pathogen and cellular nucleic acid 
from the plasma of fetal cord blood and 
maternal peripheral blood
Above-stored plasmas were thawed to room tem-
perature. The precipitated protein was cleared by 
centrifugation at 1,500g for 5 minutes. Pathogens and
cells in the cleared plasma layer (0.5 mL) were precipi-
tated by mixing with 100L  PEG/NaCl solution (20%
PEG 8000, 2.5 M NaCl) at room temperature for 30
minutes. The precipitate was collected by centrifuga-
tion at 12,000 rpm for 10 minutes. Pathogens and 
cellular nucleic acid were purified by 200L phenol
extraction and finally dissolved in 250L TE buffer.
Q-PCR assay using Taqman probe
The assay was performed in a PE 7700 Q-PCR thermal
cycler following the manufacturer’s instructions (Applied
Biosystems, Foster City, CA, USA). Q-PCR assay was
modified in our laboratory. Reaction was in a volume
of 20L containing 1PCR buffer [50 mM Tris–HCl,
10 mM KCl, 5 mM (NH4)2SO4, 2 mM MgCl2 (pH 8.3)],
0.2 mM of each dNTP, 0.5 unit of FastStart Taq (Roche
Applied Science, Indianapolis, IN, USA), 0.375M of
each primer, 0.25M of Taqman probe (5 labeled with
FAM and 3 labeled with BHQ, purified by PAGE or
HPLC), and various amounts of template DNA (2L).
The assay was performed using a two- or three-step
method, that is: initial steps included hold at 50 C 
for 2 minutes and 95 C for 4 minutes, then 35–60
cycles of 95 C for 15 seconds and 60 C for 1 minute
or 95 C for 15 seconds and 55 C for 30 seconds 
and 72 C for 30 seconds. After the reaction, the linear
plot (cycle number vs. fluorescence value), standard
curve, and copy number report table were collected 
for analysis. The presence of genomic DNA as the 
successful preparation of template DNA was moni-
tored using primers specific to the human -globin
gene. The primer sequences used to generate the posi-
tive control plasmid for Q-PCR are listed in Table 1.
The primer and probe sequences for the Q-PCR are
available on request. The concentration, expressed in
copies per milliliter, was calculated using the following
equation:
Taiwanese J Obstet Gynecol • June 2006 • Vol 45 • No 2 115
Pathogen Analyses Using Q-PCR
C  Ó 
VDNA
VPCR 
1
VEXT
( )L
Table 1. PCR primers used to generate the positive control plasmid for Q-PCR
Name F Primer R primer
Name of Amplicon
plasmid clone (bp)
HBV CTTCCAGGAACATCAACTACC AAAGCCCTGCGAACCACTGA pHBV 231
HCMV CCTAGTGTGGATGACCTACGGGCCA CAGACACAGTGTCCTCCCGCTCCTC pCMV 75
CT GAAGACGGTTAATACCCGCTG GATGGGGTTGAGACCATCCAC pCT 398
NG GTCTAGGGTGCGCTCTGCTT AGCCGCCAGCATAGAGCAAC pNG 280
-globin ACACAACTGTGTTCACTAGC GTCTCCACATGCCCAGTT — 189
HBVhepatitis B virus; HCMVhuman cytomegalovirus; CTChlamydia trachomatis; NGNeisseria gonorrhoeae.
where C is the target concentration in serum (copies/
mL); Ó, the target quantity (copies) determined by
sequence detector in PCR; VDNA, the total volume of
DNA obtained after extraction; typically 250L per
extraction; VPCR, the volume of DNA solution used for
PCR, typically 2L; and VEXT is the volume of serum
extracted, typically 200L.
Statistical analysis
Data obtained from the laboratory were analyzed using
Microsoft Excel’s descriptive statistics. Deductive sta-
tistics using SPSS 11.0 paired-samples t test. A p value
of less than 0.05 was statistically significant.
Results
We used quantitative PCR to analyze all 29 samples of
maternal blood and paired fetal umbilical cord blood.
The maternal HBV DNA detection rate was 51.72% 
with an average value of 646,804.18 copies/mL, while
the median was 76.58 copies/mL and the range was
1.42–4,598,712 copies/mL. The HCMV DNA positivity
rate was 10.34% with an average value of 6,805.2 copies/
mL, while the median was 2,938.12 copies/mL and the
range was 10.26–17,467.22 copies/mL. C. trachomatis
DNA positivity rate was 3.45%, and the number of DNA
copies was 672.93 copies/mL. N. gonorrhoeae DNA was
not detected in the maternal blood. The internal control
-globin gene DNA average value was 1,431.7 copies/mL,
while the median was 150.3 copies/mL and the range
was 1.08–7,567.85 copies/mL. In the paired samples of
fetal umbilical cord blood, the HBV DNA detection rate
was 27.59%, while the average value was 36,789.54
copies/mL, the median was 3.21 copies/mL and the
range was 1.77–294,286.24 copies/mL. C. trachomatis
DNA positivity rate was 10.34%, while the average
value was 10.21 copies/mL, the median was 10.02
copies/mL, and the range was 4.57–16.02 copies/mL;
N. gonorrhoeae DNA positivity rate was 3.45%, and the
number of copies was 1,135.54 copies/mL. HCMV DNA
was not detected in the cord blood. The internal control
-globin gene DNA average value was 101,925.3 copies/
mL, while the median was 102 copies/mL, and the range
was 11.67–1,321,264.1 copies/mL (Figure; Table 2).
Taiwanese J Obstet Gynecol • June 2006 • Vol 45 • No 2116
G.Q. Hou, et al
Table 2. Quantitative analysis of pathogen DNA in 29 serum samples of maternal and cord blood
Positive Mean Median Range 
Pathogen
number (copies/mL) (copies/mL) (copies/mL)
-globin
MB 29 1,431.66 150.28 1.08–7,567.85
CB 29 101,925.30 101.99 11.67–1,321,264.08
HBV
MB 15 646,804.18 76.58 1.42–4,598,712.00
CB 8 36,789.54 3.21 1.77–294,286.31
HCMV
MB 3 6,805.20 2,938.12 10.26–17,467.22
CB 0 — — —
CT
MB 1 672.95 — 672.95
CB 3 10.21 10.02 4.57–16.62
NG
MB 0 — — —
CB 1 1,135.54 — 1,135.54
HBVhepatitis B virus; HCMVhuman cytomegalovirus; CTChlamydia trachomatis; NGNeisseria gonorrhoeae;
MBmaternal blood; CB cord blood.
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Figure. Percentage of pathogen DNA in 29 samples of mater-
nal blood and fetal cord blood using Q-PCR. HBVhepatitis
B virus; HCMVhuman cytomegalovirus; CTChlamydia
trachomatis; NGNeisseria gonorrhoeae. 
HBV DNA was detected in 51.72% of maternal blood
and 27.59% of cord blood, while the HBV DNA positiv-
ity rate was significantly higher in maternal blood than
in cord blood (t0.022). The average value of mater-
nal blood HBV DNA and cord blood HBV DNA was
646,804.18 and 36,789.54 copies/mL, respectively.
Maternal blood HBV DNA concentration was higher
than cord blood HBV DNA concentration, but did not
reach statistical significance (t0.114). We also
found that in the 12 cases of HBsAg(–) mothers, the
HBV DNA average value was 488,305.20 copies/mL;
while for the three cases of HBsAg(+) mothers, the
HBV DNA average value was 959,359.38 copies/mL,
with no significant statistical differences (p0.598).
Discussion
HBV infection is caused by a small, partial double-
stranded DNA virus. The HBV genome measures approx-
imately 3.2 kbp. The major modes of HBV transmission
are contact with blood and bodily fluids and vertical
transmission from mothers to newborns. In this study,
the high rate of HBV infection found in fetal cord blood
was the result of vertical transmission from mother to
infant during the perinatal period [5,6].
Nagata et al [7] reported the use of Q-PCR to test
the responses of chronic HBV patients to interferon
therapy and found that the HBV DNA values of periph-
eral blood in HBsAg(–) and anti-HBs(+) patients were
still positive, but that the HBV DNA concentration was
usually less than 400 copies/mL. High values of HBV
DNA signified that the virus was presently replicating
or that the liver was undergoing progressive damage
[8]. Chen et al [9] analyzed 1,762 pregnant HBV carri-
ers and perinatal mothers to infant transmission rate
and found that the HBsAg positivity rate during preg-
nancy was 8.3% (147/1,762), among which 33.3% were
HBeAg positive (49/147), 71.4% of the newborns were
HBsAg positive in the gastric fluid (50/70), 55.7% 
were HBsAg positive in the maternal breast milk (34/61),
and 20.6% were HBsAg positive in the newborn blood
(13/63). At the same time, Chen et al [9] found that if
maternal HBsAg and HBeAg were both positive, then
the newborn’s blood HBsAg positivity rate was 81.8%. If
only the mother was HBsAg positive, the risk of vertical
transmission decreases to 18.6%.  Vaginal delivery and
cesarean section revealed no differences in vertical trans-
mission rates. HBV infection is a widespread disease in
those of Chinese descent; its prevalence, determined
using general antigen screening, is 10–20%, and when
we used Q-PCR to test the 29 samples of maternal and
fetal cord blood, the HBV DNA detection rates were
51.72% and 27.59%, respectively. The HBV DNA posi-
tivity rate of the maternal blood was significantly higher
than that of the fetal cord blood. For those who were
HBsAg(+), the HBV DNA positivity rate was significantly
higher than in those who were HBsAg(–). However, we
analyzed 29 samples of maternal blood HBsAg(–)
(12/29) and HBsAg(+) (3/29) for HBV DNA concen-
tration and found that serum HBsAg(–) samples had
HBV DNA average values of 488,305.20 copies/mL; and
HBsAg(+) samples had HBV DNA average values of
959,359.38 copies/mL (p0.598), which showed no
statistically significant difference. In our study using the
Q-PCR technique, the HBV detection rate was higher
than those reported in the literature.
The sensitivity of using PCR technology to diagnose
congenital HCMV infection from the amniotic fluid is
80%, and the specificity is 100% [10]. The sensitivity
can reach 75% when ELISA is used to search for cord
blood anti-HCMV IgM antibodies, whereas viral culture
sensitivity reaches only 30%. In the US, female serum
anti-HCMV antibody positivity rate was 55–85% during
the reproductive age, with the rate of primary HCMV
infection during pregnancy being 0.7–4%, while the 
rate of persistent infections was 13.5% [11]. Pregnant
women from mainland China had a serum anti-HCMV
IgG positivity rate as high as 94.6%, anti-HCMV IgM
positivity rate of around 3.1–13.44%; the newborn blood
or cord blood anti-HCMV IgM positivity rate was
around 0.6–8.5% and urine HCMV-DNA positivity rate,
6.5–27.3%. There was no gender predilection for HCMV
infection. In Singapore, Wong et al [12] used the ELISA
method to screen for serum HCMV IgG in 120 pregnant
women and found the prevalence to be 87%. In Egypt,
Nawawy et al [13] used the ELISA method to test 150
pregnant women and their newborns for serum HCMV
IgG and IgM, HBsAg, HBeAg, and Toxoplasma-IgG. In
women, they found a prevalence of IgM with HCMV IgG
of 96%, a prevalence of HBsAg of 8%, a prevalence of
Toxoplasma-IgG of 43%, and vertical transmission rate
of 33%. The newborn HCMV IgG rate was 96% and
HBsAg rate was 17%, while HCMV IgM and HBeAg
were not detected.
We used real-time Q-PCR to test 29 samples of
maternal blood and fetal cord blood. The HCMV DNA
positivity rate was 10.34% (3/29), and no HCMV DNA
was found in the fetal cord blood. This shows that the
cord blood is relatively more pure with respect to
HCMV. In this study, the HCMV DNA positivity rate was
lower than those reported in the literature.
Zhang et al [14] used the PCR technique to 
analyze 772 samples from pregnant women nearing
labor and found that the rate of positive results for 
C. trachomatis in the cervix was 11.3% (87/772), with a
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vertical transmission rate of 37% (amniotic fluid, new-
born conjunctivae, and nasopharyngeal swab sample
positivity). However, C. trachomatis was not detected in
the 81 samples of cord blood, leading to the conclu-
sion that ascending sexual infection is an important
route of intrauterine fetal infections. Similarly, Dong 
et al [15] used the PCR technique to screen 120 sam-
ples of cervical discharge during early pregnancy, and
found a positivity rate of 8.3% (10/120) for C. trachomatis
DNA in the cervix, while the C. trachomatis DNA positiv-
ity rate was 5.1% (3/59) in chorion obtained from
early abortions. In Hungary, C. trachomatis infection
rate during pregnancy was around 5.74% [16]. In the
US, C. trachomatis infection comprised 25–50% of
pelvic inflammatory disease, and 50–80% of patients
with C. trachomatis infection were without symptoms. In
Bissau, one researcher found that the N. gonorrhoeae
infection rate in the female reproductive tract was 17%
(34/200) [17]. According to the socioeconomic status
level in the US, N. gonorrhoeae infection rates in preg-
nant women ranged from 0.5% to 10%, and if the mater-
nal reproductive tract was infected with N. gonorrhoeae,
there was a vertical transmission rate of 30–40% which
caused ophthalmia neonatorum. For asymptomatic
women, the C. trachomatis infection rate in their repro-
ductive tracts ranged from 6.1% to 10.1%, and the 
N. gonorrhoeae infection rate was 2.3% [18,19]. Honohan
et al [20] reported a microbial contamination rate of
fetal cord blood of 13%, with low microbial load and
low pathogenicity. We used Q-PCR to test 29 samples
of maternal blood and fetal cord blood from Hualien’s
Tzu-Chi Medical Center and found C. trachomatis DNA
detection rates of 3.45% (1/29) and 10.34% (3/29),
respectively; N. gonorrhoeae DNA within the cord blood
was 3.45% (1/29), and no N. gonorrhoeae DNA was
detected in the maternal blood. These results were sim-
ilar to those reported in the literature.
We did not detect pathogen DNA in the maternal
blood but found pathogen DNA in fetal cord blood,
like that of N. gonorrhoeae. Possible reasons include sub-
detectible threshold levels of bacteria in the maternal
blood. The cord blood infection may have come from
an ascending sexual infection that may have risen from
maternal sexual activities with an infected partner. In
addition, the sample could have been contaminated.
During our data analyses, we unexpectedly found a
high incidence of pathogen DNA in both maternal and
cord blood samples, and hence repetitive assays were
performed to ensure no false-positive results in our lab-
oratory. It would be desirable to conduct a prospective
study of these pregnant women for asymptomatic infec-
tion as well as for the newborns.
We feel that using PCR technology to detect cord
blood pathogenic infections is rapid, sensitive, and 
specific. Our research disclosed significant pathogen
infection in newborns. In addition, we would favor path-
ogen screening in cord blood banks using Q-PCR to
decrease infection in transplant recipients.
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